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Introduction: The majority of patients with coronary artery disease (CAD) are eligible for 
lipid-lowering drugs, yet most of them are sub-optimally managed. A Community Health 
information Network integrated with Computer-based Clinical Decision Support Systems 
is an effective communication modality to facilitated guideline implementation. 
Objeetlves: To study the impact of "smart CHIN - CDSS communicator" in CAD for sec- 
ondary prevention. 
Methods: Patients were from 113 demographically-matched clinics, 55 clinics in the 
intervention group, and 57 clinics following routine practice (control). We developed a 
computerized engine that incorporates computerized atabases and creates a compre- 
hensive prospective registry including demographics, diagnosis, laboratory results and 
medication. This system detected patients requiring screening and who were eligible for 
lipid lowering drugs, then mailed automatic remainders to the primary medical teams in 
the intervention group clinics recommending screening or medium dose of statins. Peri- 
odic reinforcement of reminding is performed every 4 months. 
Results: Out of 2528 patients with CAD who were enrolled, by August 2001, 1558 had 
been followed for 4 months. Those in an intervention group clinic demonstrated an 
improved lipid profile screening (65% vs 50%) (p<0.01), and a higher percent of patients 
achieved target levels (21% vs 13%) (p<0.00Ol). 
Conclualons: A computerized automatic reminder generator was shown to have a sig- 
nificantly positive short- term effect on use and results of secondary prevention mea- 
sures. This intervention is expected to have a major impact on the clinical course of CAD 
disease. Clinical evaluation of cardiac event reduction will take place in January 2002, 
after one year of follow-up. 
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Background: Plaque instability and rupture are central features of atherothrombotic syn- 
dromes. Vulnerable plaques have a decreased number of vascular smooth muscle cells 
(VSMC), a rudimentary extracallular matrix protein content and an increased number of 
monocytes/macrophages (MM), in their fibrous caps. We have shown that VSMC death 
is clue to interaction of these cells with MM activated by M-CSF. Furthermore, such 
VSMC killing by MM requires the tight binding of MM to VSMC mediated by CD11b- 
CD18. We hypothesized that, once tightly bound to VSMC, MM kill VSMC by activating 
their Fas death pathway, thus leading to apoptosis of VSMC. 
Methods: FasL and Fas expression were studied on VSMC and MM co-cultured for 
72hours, in the presence of M-CSF (100ng/ml). Monocytes were identified by CD14- 
FITC staining. Similar experiments were conducted using a Fas-Fc fusion protein that 
inhibits FasL/Fas mediated apoptosis. 
Results: As shown previously, apoptosis of VSMC was induced by MM, but only in the 
presence of M-CSF (57.8_+ 0.8%). We used a pan-caspase inhibitor (ZVAD fmk) to show 
that death of VSMC induced by M-CSF-ectivated MM was indeed by apoptosis. When 
VSMC were pre-incubated with ZVAD fmk (10kLM/ml), apoptosis induced by M-CSF acti- 
vated MM was completely abrogated (15.4_+0.4%), and similar to control VSMC with 
monocytes depdved of M-CSF (12.2_+1.6%). Next, we tested the role of Fas/Fas-ligand in 
the apoptotic death of VSMC induced by M-CSF-activated MM. Fas expression was 
detected only on VSMC and not the surface of MM. Fas-L was detected on MM. VSMC 
apoptosis triggered by M-CSF-activated MM was nearly completely prevented when co- 
cultures were treated with huReFas-Fc fusion protein (2~g/ml) (27.0i-_ 1.0%, p<O.O05 vs. 
identical conditions, except for the omission of huReFas-Fc). This apoptotic index was 
not different from that seen in control VSMC with unactivated MM (15.7+ 3.5%, p_<O.06) 
(with or without huReFas-Fc, 2pg/ml). 
Conclusions: This data suggests a mechanism for plaque destabilization and rupture 
where VSMC death induced by M-CSF-activatad MM is by apoptosis and the FasL/Fas 
death receptor pathway could play a major role in this process. 
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Background: The inflammatory infiltrate in unstable plaque is unusual in that it contains 
a specialized subset of clonally expanded CD4+ T calls that lack the CD28 molecule. The 
functional profile and the signals required to activate CD4+CD28- T calls in the plaque 
are not known. 
Methods: CD4+CD28-T cell clones (n=60) were isolated from 3 patients with plaque 
instability and subjected to gene profiling. Selective expression of genes was confirmed 
by PCR and FACS analysis and gene products of interest were further analysed on 
freshly harvested peripheral blood lymphocytes. Functional activities of T cell clones 
were examined in cytotoxicity assays on endothelial target cells. 
Results: CD4+CD28- T cell clones were distinct from classical CD4+CD28+ T cells in 
that they possessed a cytolytic machinery and killed endothelial cells. They also overex- 
pressed CD161, a C type lectin typically found on NK cells where it amplifies cytotoxic 
function. Frequencies of CD4+CD161+ T ceils were twofold increased in the blood of 
patients with unstable angina (17.6 %) as compared to stable angina (9.8 %, p<0.003) 
and matched controls (7.9 %, p=<0.001). We hypothesized that the appearance of 
CD161 on CD4 T cells was a consequence of recent activation and explored the ability of 
pro-inflammatory cytokines (IL-2, IL-12, IL-15, and IL-18) to upregulate CD161. Culture 
of CD4+CD28- but not CD4+CD28+ T cell clones in IL-12 promptly induced CD161 on 
the surface, even in the absence of T cel~ receptor crosslinking. 
Conclusions: Patients with ACS have T cells that can be activated in response to IL-12 
without he need for antigen recognition. The accumulation of CD4+CD161+ cells in the 
circulation of these patients indicates that a marked proportion of their T cells are consti- 
tutively activated, likely by the exposure to the pro-inflammatory cytokine IL-12. Expres- 
sion of the lectin CD161 prepares these T cells for rapid transmigration through 
endothelial cells, preferred recruitment into tissue lesions and accelerated cytotoxicity. 
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Background: Monocyte chemotactic protein 1 (MCP-1), which is synthesized by vascular 
cells, is a chemoattractant for monocytes and has been implicated in a wide range of 
acute and chronic inflammatory processes characterized by monocyte infiltration, includ- 
ing atheresclerosis. However, it is unclear whether MCP-1 is able to modulate vascular 
smooth muscle cell (VSMC) proliferation. We assessed the effect of MCP-1 on VSMC 
proliferation and its interaction with serotonin (5-HT), a mitogen for VSMCs. 
Methods: Growth-arrested VSMCs were stimulated with different concentrations of MCP- 
1 (25-200 ng/ml) and 5-HT (5 and 50 microM) in serum-free medium. DNA synthesis in 
VSMCs was measured by [3H]thymidine incorporation. 
Results: 5-HT at a concentration of 5 or 50 microM significantly stimulated DNA Synthe- 
sis by 1.8- or 2.1-fold over the control value, respectively (p < 0.0001 ). However, MCP-1 
at concentrations tested did not have any significant effect on DNA synthesis. Even 
though MCP-1 (50 ng/ml) by itself is not mitogenic, when added to 5-HT, it significantly 
amplified the mitogenic effect of 5-HT compared with that of 5-HT alone (p < 0.0001). 
The 5-HT2A receptor antagonist serpogrelate (10 microM) and its major metabolits M-1 
(0.1 microM), pertussis toxin (10 ng/ml), Src family protein tyresine kinase (PTK) inhibitor 
PP2 (1 microM), protein kinase C (PKC) inhibitor Ro31-8220 (0.1 microM), and MAPK 
kinase inhibitor PD098059 (10 microM) significantly inhibited the mifogenic effect of 5-HT 
and its interaction with MCP-I. Anti-MCP-I antibody (2 microg/ml) and the JAK2 inhibitor 
AG490 (10 microM) significantly inhibited the interaction of MCP-1 with 5-HT. Further, the 
amplified mitogenic effect of 5-HT with MCP-1 was completely reversed by the combined 
use of serpogrelate with anti-MCP-1 antibody. 
Conclusions: Our results suggest that MCP-1 amplifies the mitogenic effect of 5-HT on 
VSMCs. The mitogenic effect of 5-HT may be mediated by the G protein-Src family PTK- 
PKC-MAPK pathway. The activation of JAK2/STAT3 pathway by MCP-1 in addition to the 
MAPK pathway by 5-HT may explain the potentiating effect of MCP-1 on 5-HT-induced 
mitogenesis. 
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and p38 MAPK in Human Endothelial Cells 
Martina Werle. Katherina Hanna, Joerg Kreuzer, Department of Cardiology, University of 
Heidelberg, Heidelberg, Germany. 
Background: Activation of vascular endothelial cells (EC) plays an important pathogenic 
role in the development of atherosclerosis. Monocyte chemoattractant protein-1 (MCP-1) 
is a potent chemoattractant of monocytes. Besides induction of monocyte recruitment, it
has been suggested that MCP-1 can also affect cellular responses of EC. 
Methods: We now investigated whether MCP-1 activated the three major mitogen acti- 
vated protein (MAP)-kinases extracellular signal-regulated kinase (ERK), c-Jun amino 
terminal kinase (JNK) and p38 MAPK. 
Results: Stimulation of EC with MCP-t induced a time-dependent activation of all three 
